Registry for blind individuals with sleep problems

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a patient registry for individuals who are totally blind and may experience Non-24-hour sleep-wake disorder. Participants will engage in a phone survey to provide information about their vision impairment and sleep issues. The registry will help researchers understand sleep-related problems in blind individuals and may facilitate future clinical studies and treatment investigations. The data collected will also raise awareness about Non-24 and its impact on this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects or legal guardians must be at least 18 years of age to participate in the telephone survey. Parents or legal guardians may represent children from 0 through 17 years who meet the following criteria.
2. Subjects must be blind.
3. Subjects must have some self-described problem with sleep or daytime sleepiness.

Where it's running

• Vanda Pharmaceuticals
  Washington D.C., District of Columbia, United States Recruiting

Study contacts

• Study coordinator: Vanda Pharmaceuticals
• Phone: (202) 734-3400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ponesimod for moderately to severely active ulcerative colitis: a treatment study

  This study tests whether ponesimod can help people with moderately to severely active ulcerative colitis who have not responded well to other treatments.

  Recruiting at 2 sites Phase 3 Vanda Pharmaceuticals · Chula Vista, California and 1 other locations · NCT07686081

• Tradipitant for GLP-1R agonist–related nausea and vomiting in adults with overweight or class I–II obesity

  This trial will test if tradipitant can reduce nausea and vomiting caused by GLP-1 receptor agonist weight-loss medicines in adults who are overweight or have class I–II obesity.

  Recruiting at 3 sites Phase 3 Vanda Pharmaceuticals · Los Angeles, California and 9 other locations · NCT07446439

• Ponesimod in adults with moderate-to-severe chronic plaque psoriasis

  This study tests whether ponesimod is safe and helps clear moderate-to-severe plaque psoriasis in adults aged 18–65.

  Recruiting at 10 sites Phase 3 Vanda Pharmaceuticals · Glendale, Arizona and 9 other locations · NCT07362017

• Eight-week test of VSJ-110 versus placebo for dry eye

  This eight-week test will see if VSJ-110 reduces dry eye symptoms better than a placebo in adults with dry eye.

  Recruiting at 2 sites Phase 2 Vanda Pharmaceuticals · Newport Beach, California and 4 other locations · NCT07179055

• Iloperidone for adults with uncontrolled high blood pressure

  We are testing whether iloperidone can lower blood pressure in adults whose blood pressure stays high despite at least 8 weeks of one or more blood pressure medications.

  Recruiting at 18 sites Phase 2 Vanda Pharmaceuticals · Phoenix, Arizona and 27 other locations · NCT07090161

• Testing whether stopping iloperidone long-acting injection causes symptom return in adults with schizophrenia.

  This trial tests whether iloperidone long-acting injection prevents symptom worsening compared with placebo in adults with schizophrenia.

  Recruiting at 22 sites Phase 3 Vanda Pharmaceuticals · Rogers, Arkansas and 21 other locations · NCT06961968

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.